By Fineline Cube China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced plans to establish a $1.4 billion CRDMO service center in Singapore. The facility, supported by Singapore’s Economic Development Board (EDB), will include a biologic drug R&D service center and large-scale production plant, adding 120,000 liters of biopharmaceutical capacity by 2026.
Project Details
The Singapore center will create 1,500 R&D and production jobs, marking WuXi’s largest overseas investment. The site will offer end-to-end services from drug discovery to commercial manufacturing, leveraging Singapore’s strategic location and pro-business policies.
Strategic Milestone
The move follows WuXi’s expansions in China, Ireland, Germany, and the U.S. Singapore’s EDB cited the project as a boost to the city-state’s biotech ecosystem, enhancing its appeal as a hub for global life sciences firms.-Fineline Info & Tech